Güllü Görgün

5.8k citations

74 papers · 3.8k indexed · h-index 31

Molecular Biology top 5%
Hematology top 0.5%
Oncology top 2%
Immunology top 2%
Genetics top 1%

Co-authors: Kenneth C. Anderson Francine M. Foss Teru Hideshima John G. Gribben Nikhil C. Munshi Noopur Raje Paul G. Richardson Kenneth B. Miller
Topics: Multiple Myeloma Research and Treatments (38 papers)Protein Degradation and Inhibitors (19 papers)Histone Deacetylase Inhibitors Research (11 papers)
Cited by: Hematology Genetics Immunology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation Nature Communications
Partner nations: United States United Kingdom Japan

In The Last Decade

Güllü Görgün

73 papers receiving 3.8k citations

Peers

Countries citing papers authored by Güllü Görgün

Since Specialization

Citations

This map shows the geographic impact of Güllü Görgün's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Güllü Görgün with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Güllü Görgün more than expected).

Fields of papers citing papers by Güllü Görgün

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Güllü Görgün. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Güllü Görgün. The network helps show where Güllü Görgün may publish in the future.

Co-authorship network of co-authors of Güllü Görgün

This figure shows the co-authorship network connecting the top 25 collaborators of Güllü Görgün. A scholar is included among the top collaborators of Güllü Görgün based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Güllü Görgün. Güllü Görgün is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) 2022 ·Journal for ImmunoTherapy of Cancer ·Hussein A. Tawbi,Caroline Robert,Jan C. Brase,Daniel Gusenleitner,Eduard Gasal,James E. Garrett,Alexander Savchenko,Güllü Görgün,Keith T. Flaherty,Antoni Ribas,Reinhard Dummer,Dirk Schadendorf,Georgina V. Long,Paul Nathan,Paolo A. Ascierto	19
2	Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment 2017 ·Blood ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Douglas W. Sborov,Craig C. Hofmeister,James E. Bradner,Teru Hideshima,Kenneth C. Anderson,Güllü Görgün	3
3	The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival 2016 ·Nature Communications ·Hiroto Ohguchi,Teru Hideshima,Manoj Bhasin,Güllü Görgün,Loredana Santo,Michele Cea,Mehmet Samur,Naoya Mimura,Rikio Suzuki,Yu Tai,Ruben D. Carrasco,Noopur Raje,Paul G. Richardson,Nikhil C. Munshi,Hideo Harigae,Takaomi Sanda,Juro Sakai,Kenneth C. Anderson	75
4	Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells 2015 ·PLoS ONE ·Rikio Suzuki,Shohei Kikuchi,Takeshi Harada,Naoya Mimura,Jiro Minami,Hiroto Ohguchi,Yasuhiro Yoshida,M. Sagawa,Güllü Görgün,Diana Cirstea,Francesca Cottini,Jana Jakubı́ková,(unknown),Dharminder Chauhan,Paul G. Richardson,Nikhil C. Munshi,Kiyoshi Ando,Teruhiro Utsugi,Teru Hideshima,Kenneth C. Anderson	19
5	Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma 2015 ·Blood Cancer Journal ·Teru Hideshima,Francesca Cottini,Hiroto Ohguchi,Jana Jakubı́ková,Güllü Görgün,Naoya Mimura,YT Tai,Nikhil C. Munshi,Paul G. Richardson,K C Anderson	53
6	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma 2014 ·Molecular Cancer Therapeutics ·Diana Cirstea,Loredana Santo,Teru Hideshima,Homare Eda,Yuko Mishima,Neeharika Nemani,Anuj Mahindra,Andrew J. Yee,Güllü Görgün,Yiguo Hu,Hiroto Ohguchi,Rikio Suzuki,Francesca Cottini,Sylvie M. Guichard,Kenneth C. Anderson,Noopur Raje	24
7	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition 2014 ·Cancer Research ·Naoya Mimura,Teru Hideshima,Toshiyasu Shimomura,Rikio Suzuki,Hiroto Ohguchi,(unknown),Shohei Kikuchi,Yasuhiro Yoshida,Francesca Cottini,Jana Jakubı́ková,Diana Cirstea,Güllü Görgün,Jiro Minami,Yu‐Tzu Tai,Paul G. Richardson,Teruhiro Utsugi,Atsushi Iwama,Kenneth C. Anderson	66
8	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs 2013 ·Leukemia ·Diana Cirstea,Teru Hideshima,Loredana Santo,Homare Eda,Yuji Mishima,Neeharika Nemani,Yiguo Hu,Naoya Mimura,Francesca Cottini,Güllü Görgün,Hiroto Ohguchi,Rikio Suzuki,Hannes Loferer,Nikhil C. Munshi,K. C. Anderson,Noopur Raje	47
9	Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma 2012 ·Clinical Cancer Research ·Claire Fabre,Naoya Mimura,Kathryn Bobb,Sun‐Young Kong,Güllü Görgün,Diana Cirstea,Yiguo Hu,Jiro Minami,Hiroto Ohguchi,Jie Zhang,Jeffrey Meshulam,Ruben D. Carrasco,Yu‐Tzu Tai,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson	66
10	Intrinsic Modulation of Lymphocyte Function by Stromal Cell Network: Advance in Therapeutic Targeting of Cancer 2011 ·Immunotherapy ·Güllü Görgün,Kenneth C. Anderson	5
11	Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma 2010 ·Molecular Cancer Therapeutics ·Diana Cirstea,Teru Hideshima,Scott J. Rodig,Loredana Santo,Samantha Pozzi,Sonia Vallet,Hiroshi Ikeda,Giulia Perrone,Güllü Görgün,Kishan Patel,Neil Desai,Peter Sportelli,Shweta Kapoor,Shireen Vali,Siddhartha Mukherjee,Nikhil C. Munshi,Kenneth C. Anderson,Noopur Raje	136
12	PI3K/p110δ is a novel therapeutic target in multiple myeloma 2010 ·Blood ·Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Giulia Perrone,Naoya Miura,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Loredana Santo,Sonia Vallet,(unknown),Elisabetta Calabrese,Güllü Görgün,Noopur Raje,Paul G. Richardson,Nikhil C. Munshi,Brian J. Lannutti,Kamal D. Puri,Neill A. Giese,Kenneth C. Anderson	156
13	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition 2010 ·Oncogene ·Loredana Santo,Sonia Vallet,Teru Hideshima,Diana Cirstea,Hiroshi Ikeda,Samantha Pozzi,Kishan Patel,Yutaka Okawa,Güllü Görgün,Giulia Perrone,Elisabetta Calabrese,Murray Yule,Matthew Squires,Marco Ladetto,Mario Boccadoro,Paul G. Richardson,Nikhil C. Munshi,K C Anderson,Noopur Raje	114
14	Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia 2005 ·British Journal of Haematology ·(unknown),David Zahrieh,Güllü Görgün,Aihong Li,Jianbiao Zhou,Sascha Ansén,Laura Z. Rassenti,John G. Gribben	37
15	A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease 2004 ·Bone Marrow Transplantation ·K B Miller,Todd F. Roberts,Geoffrey Chan,David P. Schenkein,(unknown),Kellie Sprague,Güllü Görgün,Valerie Relias,Howard Grodman,Anita Mahajan,Francine M. Foss	53
16	Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene 2002 ·Leukemia Research ·(unknown),Xuejun Tian,Güllü Görgün,Alexander Urbano,Francine M. Foss	32
17	Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines 2002 ·Cellular Signalling ·(unknown),Güllü Görgün,Alexander Urbano,Francine M. Foss	49
18	Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells 2002 ·Biochemical Pharmacology ·Alexander Urbano,Güllü Görgün,Francine M. Foss	14
19	ALTERED BIOLOGICAL ACTIVITY ASSOCIATED WITH C-TERMINAL MODIFICATIONS OF IL-7 2002 ·Cytokine ·Güllü Görgün,(unknown),(unknown),Adnan Menevşe,Francine M. Foss	3
20	Induction of apoptosis in lymphoid leukemia cells: differential effects of rar and rxr retinoids with dexamethasone 2000 ·Blood ·Güllü Görgün,Francine M. Foss	1

About Güllü Görgün

Güllü Görgün is a scholar working on Hematology, Immunology and Genetics, having authored 74 papers that have together received 3.8k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (19 papers) and Histone Deacetylase Inhibitors Research (11 papers). The work is most often cited by research in Hematology (1.5k citations), Genetics (894 citations) and Immunology (1.4k citations). Güllü Görgün has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Kenneth C. Anderson, Francine M. Foss, Teru Hideshima, John G. Gribben, Nikhil C. Munshi, Noopur Raje, Paul G. Richardson, Kenneth B. Miller, Alan G. Ramsay and Rifca Le Dieu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact